vs
Side-by-side financial comparison of Cue Biopharma, Inc. (CUE) and Entrada Therapeutics, Inc. (TRDA). Click either name above to swap in a different company.
Cue Biopharma, Inc. is the larger business by last-quarter revenue ($21.9M vs $20.6M, roughly 1.1× Entrada Therapeutics, Inc.). Cue Biopharma, Inc. runs the higher net margin — 7.2% vs -84.4%, a 91.6% gap on every dollar of revenue. On growth, Cue Biopharma, Inc. posted the faster year-over-year revenue change (1292.3% vs -65.2%). Over the past eight quarters, Cue Biopharma, Inc.'s revenue compounded faster (257.5% CAGR vs 6.4%).
Cue Biopharma is a clinical-stage biotechnology company focused on developing novel targeted immunotherapies for cancer, autoimmune disorders, and inflammatory diseases. Its proprietary platform enables precise T-cell activity modulation, with core operations in North America and global pharma partnerships to advance lead product candidates through clinical trials.
Entrada Therapeutics is a clinical-stage biotechnology firm developing transformative intracellular therapies for serious rare diseases and high-unmet-need disorders. Its pipeline covers neuromuscular, metabolic, and central nervous system segments, serving global patients via healthcare partnerships.
CUE vs TRDA — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2025
| Metric | | |
|---|---|---|
| Revenue | $21.9M | $20.6M |
| Net Profit | $1.6M | $-17.3M |
| Gross Margin | — | — |
| Operating Margin | 9.0% | -106.0% |
| Net Margin | 7.2% | -84.4% |
| Revenue YoY | 1292.3% | -65.2% |
| Net Profit YoY | 116.7% | -173.8% |
| EPS (diluted) | $0.05 | $-0.42 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $21.9M | — | ||
| Q3 25 | $2.1M | — | ||
| Q2 25 | $3.0M | — | ||
| Q1 25 | $421.0K | $20.6M | ||
| Q4 24 | $1.6M | $37.4M | ||
| Q3 24 | $3.3M | $19.6M | ||
| Q2 24 | $2.7M | $94.7M | ||
| Q1 24 | $1.7M | $59.1M |
| Q4 25 | $1.6M | — | ||
| Q3 25 | $-7.4M | — | ||
| Q2 25 | $-8.5M | — | ||
| Q1 25 | $-12.3M | $-17.3M | ||
| Q4 24 | — | $1.1M | ||
| Q3 24 | $-8.7M | $-14.0M | ||
| Q2 24 | $-10.2M | $55.0M | ||
| Q1 24 | $-12.3M | $23.5M |
| Q4 25 | 9.0% | — | ||
| Q3 25 | -353.4% | — | ||
| Q2 25 | -292.3% | — | ||
| Q1 25 | -2921.4% | -106.0% | ||
| Q4 24 | — | -15.7% | ||
| Q3 24 | -264.2% | -110.7% | ||
| Q2 24 | -390.6% | 56.4% | ||
| Q1 24 | -737.8% | 35.7% |
| Q4 25 | 7.2% | — | ||
| Q3 25 | -346.6% | — | ||
| Q2 25 | -287.1% | — | ||
| Q1 25 | -2911.4% | -84.4% | ||
| Q4 24 | — | 3.0% | ||
| Q3 24 | -259.6% | -71.7% | ||
| Q2 24 | -382.7% | 58.1% | ||
| Q1 24 | -719.1% | 39.7% |
| Q4 25 | $0.05 | — | ||
| Q3 25 | $-0.07 | — | ||
| Q2 25 | $-0.09 | — | ||
| Q1 25 | $-0.17 | $-0.42 | ||
| Q4 24 | — | $-0.20 | ||
| Q3 24 | $-0.17 | $-0.35 | ||
| Q2 24 | $-0.20 | $1.55 | ||
| Q1 24 | $-0.25 | $0.68 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $27.1M | $67.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $26.4M | $417.3M |
| Total Assets | $42.2M | $486.5M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $27.1M | — | ||
| Q3 25 | $11.7M | — | ||
| Q2 25 | $27.5M | — | ||
| Q1 25 | $13.1M | $67.8M | ||
| Q4 24 | $22.5M | $101.2M | ||
| Q3 24 | $32.4M | $78.0M | ||
| Q2 24 | $30.0M | $185.3M | ||
| Q1 24 | $41.0M | $68.4M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $1.0M | — | ||
| Q2 24 | $2.0M | — | ||
| Q1 24 | $3.0M | — |
| Q4 25 | $26.4M | — | ||
| Q3 25 | $13.2M | — | ||
| Q2 25 | $18.2M | — | ||
| Q1 25 | $6.6M | $417.3M | ||
| Q4 24 | $17.5M | $428.7M | ||
| Q3 24 | $25.4M | $422.4M | ||
| Q2 24 | $21.6M | $429.9M | ||
| Q1 24 | $30.0M | $269.4M |
| Q4 25 | $42.2M | — | ||
| Q3 25 | $31.6M | — | ||
| Q2 25 | $40.7M | — | ||
| Q1 25 | $22.3M | $486.5M | ||
| Q4 24 | $32.2M | $526.3M | ||
| Q3 24 | $44.8M | $554.6M | ||
| Q2 24 | $42.3M | $582.0M | ||
| Q1 24 | $54.0M | $510.8M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.04× | — | ||
| Q2 24 | 0.09× | — | ||
| Q1 24 | 0.10× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.1M | $-38.5M |
| Free Cash FlowOCF − Capex | — | $-39.7M |
| FCF MarginFCF / Revenue | — | -192.9% |
| Capex IntensityCapex / Revenue | 0.0% | 5.6% |
| Cash ConversionOCF / Net Profit | -0.68× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-58.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-1.1M | — | ||
| Q3 25 | $-9.0M | — | ||
| Q2 25 | $-3.4M | — | ||
| Q1 25 | $-8.2M | $-38.5M | ||
| Q4 24 | $-36.3M | $-31.6M | ||
| Q3 24 | $-7.5M | $-24.3M | ||
| Q2 24 | $-10.0M | $39.8M | ||
| Q1 24 | $-9.8M | $-25.5M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $-3.4M | — | ||
| Q1 25 | $-8.3M | $-39.7M | ||
| Q4 24 | $-36.4M | $-32.2M | ||
| Q3 24 | $-7.5M | $-24.9M | ||
| Q2 24 | $-10.0M | $38.8M | ||
| Q1 24 | $-9.8M | $-26.4M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -116.5% | — | ||
| Q1 25 | -1976.7% | -192.9% | ||
| Q4 24 | -2309.3% | -86.2% | ||
| Q3 24 | -225.7% | -127.3% | ||
| Q2 24 | -376.2% | 41.0% | ||
| Q1 24 | -573.0% | -44.6% |
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.9% | — | ||
| Q1 25 | 35.6% | 5.6% | ||
| Q4 24 | 4.2% | 1.7% | ||
| Q3 24 | 0.0% | 3.3% | ||
| Q2 24 | 0.4% | 1.1% | ||
| Q1 24 | 3.2% | 1.4% |
| Q4 25 | -0.68× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -27.94× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.72× | ||
| Q1 24 | — | -1.09× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CUE
| Immuno Scape Collaboration And License Agreement | $9.5M | 43% |
| BI Collaboration And License Agreement | $8.1M | 37% |
| Other | $4.3M | 20% |
TRDA
Segment breakdown not available.
